Genetic Signatures (ASX:GSS) FCF Margin % : -158.13% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Genetic Signatures FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Genetic Signatures's Free Cash Flow for the six months ended in Dec. 2023 was A$-5.70 Mil. Genetic Signatures's Revenue for the six months ended in Dec. 2023 was A$3.60 Mil. Therefore, Genetic Signatures's FCF Margin % for the quarter that ended in Dec. 2023 was -158.13%.

As of today, Genetic Signatures's current FCF Yield % is -11.59%.

The historical rank and industry rank for Genetic Signatures's FCF Margin % or its related term are showing as below:

ASX:GSS' s FCF Margin % Range Over the Past 10 Years
Min: -320.9 Med: -105.16 Max: 19.25
Current: -111.33

During the past 9 years, the highest FCF Margin % of Genetic Signatures was 19.25%. The lowest was -320.90%. And the median was -105.16%.

ASX:GSS's FCF Margin % is ranked worse than
79.73% of 222 companies
in the Medical Diagnostics & Research industry
Industry Median: -10.815 vs ASX:GSS: -111.33

Genetic Signatures FCF Margin % Historical Data

The historical data trend for Genetic Signatures's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetic Signatures FCF Margin % Chart

Genetic Signatures Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

FCF Margin %

Get a 7-Day Free Trial

-59.19

-105.16

-2.77

19.25

-96.18

Genetic Signatures Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial													34.07	-4.59	-96.44	-95.94	-158.13

Competitive Comparison of Genetic Signatures's FCF Margin %

For the Diagnostics & Research subindustry, Genetic Signatures's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genetic Signatures's FCF Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Signatures's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Genetic Signatures's FCF Margin % falls into.

Genetic Signatures FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Genetic Signatures's FCF Margin for the fiscal year that ended in Jun. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Jun. 2023 )	/	Revenue (A: Jun. 2023 )
	=	-20.545	/	21.36
	=	-96.18 %

Genetic Signatures's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-5.699	/	3.604
	=	-158.13 %

Genetic Signatures FCF Margin % Related Terms

Thank you for viewing the detailed overview of Genetic Signatures's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Genetic Signatures (ASX:GSS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Signatures Ltd (ASX:GSS) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

7 Eliza Street, Newtown, Sydney, NSW, AUS, 2042

Website

https://www.geneticsignatures.com

Genetic Signatures Ltd proprietary PCR solutions and automated workflows routinely screen for multiple infectious diseases in a single test. Rapid and accurate results facilitate improved patient management and healthcare outcomes. GSS continues to expand its global reach with direct representation in Australia, Europe, and the United States, and growing distribution partnerships. The company operates under one business segment which is the research and commercialisation of identifying individual genetic signatures to diagnose diseases and disabilities.